Last reviewed 2026-05-18 · How we verify

Pf-07940369 (pf-07940369)

Pfizer Inc. · FDA-approved active Quality 25/100

Pf-07940369 (generic name: pf-07940369) is a Not available drug developed by Pfizer Inc.. It is currently FDA-approved for Multiple Myeloma, Lymphoma, Leukemia.

At a glance

Generic name	pf-07940369
Sponsor	Pfizer Inc.
Drug class	Not available
Target	Not available
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

Multiple Myeloma
Lymphoma
Leukemia

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Pentobarbital
Phenobarbital
Rivaroxaban
Apixaban
Dabigatran
Clopidogrel
Ticagrelor
Prasugrel
Cilostazol
Dipyridamole

Key clinical trials

A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pf-07940369 CI brief — competitive landscape report
Pf-07940369 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about Pf-07940369

What is Pf-07940369?

Pf-07940369 (pf-07940369) is a Not available drug developed by Pfizer Inc., indicated for Multiple Myeloma, Lymphoma, Leukemia.

What is Pf-07940369 used for?

Pf-07940369 is indicated for Multiple Myeloma, Lymphoma, Leukemia.

Who makes Pf-07940369?

Pf-07940369 is developed and marketed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Pf-07940369?

pf-07940369 is the generic (nonproprietary) name of Pf-07940369.

What drug class is Pf-07940369 in?

Pf-07940369 belongs to the Not available class. See all Not available drugs at /class/not-available.

What development phase is Pf-07940369 in?

Pf-07940369 is FDA-approved (marketed).

What does Pf-07940369 target?

Pf-07940369 targets Not available and is a Not available.

Drug class: All Not available drugs
Target: All drugs targeting Not available
Manufacturer: Pfizer Inc. — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Multiple Myeloma
Indication: Drugs for Lymphoma
Indication: Drugs for Leukemia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing